Supplemental Figure 1. (A) Kaplan Meijer curves for patients with high or low *CD47* expression treated with CHOP or R-CHOP. (B) Kaplan Meijer curves for DLBCL patients treated with CHOP or R-CHOP

Supplemental Figure 2. (A) non-GCB have significantly higher *CD47* expression level than GCB DLBCL patients. (B) CHOP and R-CHOP treated patients have similar *CD47* expression levels.

Supplemental Figure 3. (A) Kaplan Meijer curves for DLBCL patients divided by their cell-of-origin (COO, Germinal Center B-cells (GCB) or non-GCB). (B,C) Kaplan Meijer curves to study the effect of rituximab to CHOP chemotherapy in non-GCB and GCB DLBCL patients, respectively. (D) Kaplan Meijer estimates for DLBCL patients sorted on *CD47* expression level and COO. Non-GCB DLBCL Patients with high *CD47* expression have an inferior survival.

Supplemental Figure 4. (A) Cell lines were mixed with macrophages and treated with human IgG4 isotype control antibody. Phagocytosis was calculated by determining of percentage of phagocytosed tumor cells. (B) Correlation between binding of rituximaband experiemtnal induction of phagocytosis upon combination with CD47 antbody inhibrix. (c) Correlation between binding of CD47 monoclonal antibody and experimental induction of phagocytosis upon combination with rituximab